Non-clinical safety assessment of gadoterate meglumine (Dotarem(®)) in neonatal and juvenile rats.

[1]  C. Mallio,et al.  Gadodiamide and Dentate Nucleus T1 Hyperintensity in Patients With Meningioma Evaluated by Multiple Follow-Up Contrast-Enhanced Magnetic Resonance Examinations With No Systemic Interval Therapy. , 2015, Investigative radiology.

[2]  Pascal J. Kieslich,et al.  Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. , 2015, Radiology.

[3]  David F Kallmes,et al.  Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging. , 2015, Radiology.

[4]  Shigeru Furui,et al.  High Signal Intensity in Dentate Nucleus on Unenhanced T1-weighted MR Images: Association with Linear versus Macrocyclic Gadolinium Chelate Administration. , 2015, Radiology.

[5]  P. Bruneval,et al.  Safety profiles of gadolinium chelates in juvenile rats differ according to the risk of dissociation. , 2014, Reproductive toxicology.

[6]  C. Robic,et al.  The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update , 2014, Critical reviews in toxicology.

[7]  Vincenzo Di Lazzaro,et al.  Progressive Increase of T1 Signal Intensity of the Dentate Nucleus on Unenhanced Magnetic Resonance Images Is Associated With Cumulative Doses of Intravenously Administered Gadodiamide in Patients With Normal Renal Function, Suggesting Dechelation , 2014, Investigative radiology.

[8]  Michael Derelanko,et al.  Handbook of Toxicology, Third Edition , 2014 .

[9]  Daisuke Takenaka,et al.  High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. , 2014, Radiology.

[10]  T. P. Coogan,et al.  Juvenile Animal Toxicity Assessments: Decision Strategies and Study Design , 2013 .

[11]  M. Port,et al.  Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[12]  Peter Reimer,et al.  Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines , 2013, European Radiology.

[13]  V. Runge,et al.  MRI contrast agents: Basic chemistry and safety , 2012, Journal of magnetic resonance imaging : JMRI.

[14]  Lucie Yang,et al.  Nephrogenic systemic fibrosis and class labeling of gadolinium-based contrast agents by the Food and Drug Administration. , 2012, Radiology.

[15]  L. Grosse-Wortmann,et al.  Gadolinium in pediatric cardiovascular magnetic resonance: what we know and how we practice , 2012, Journal of Cardiovascular Magnetic Resonance.

[16]  B. Wagner,et al.  Skin gadolinium following use of MR contrast agents in a rat model of nephrogenic systemic fibrosis. , 2012, Radiology.

[17]  M. Port,et al.  Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide , 2012, British journal of pharmacology.

[18]  P. Leboit,et al.  Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. , 2011, Journal of the American Academy of Dermatology.

[19]  F. Brunelle,et al.  Gd-DOTA administration at MRI in children younger than 18 months of age: immediate adverse reactions , 2011, Pediatric Radiology.

[20]  M. Port,et al.  Comparative In Vivo Dissociation of Gadolinium Chelates in Renally Impaired Rats: A Relaxometry Study , 2011, Investigative radiology.

[21]  C. Robic,et al.  Clinical, Biological, and Skin Histopathologic Effects of Ionic Macrocyclic and Nonionic Linear Gadolinium Chelates in a Rat Model of Nephrogenic Systemic Fibrosis , 2011, Investigative radiology.

[22]  C. Anderson,et al.  The biodistribution of [153Gd]Gd‐labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice , 2010, Magnetic resonance in medicine.

[23]  T. Steger-Hartmann,et al.  Impact of Renal Impairment on Long-Term Retention of Gadolinium in the Rodent Skin Following the Administration of Gadolinium-Based Contrast Agents , 2009, Investigative radiology.

[24]  T. Frenzel,et al.  Stability of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents in Human Serum at 37°C , 2008, Investigative radiology.

[25]  J. L. Abraham,et al.  Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis. , 2008, European journal of radiology.

[26]  Hanns-Joachim Weinmann,et al.  Gadolinium‐based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: The role of excess ligand , 2008, Journal of magnetic resonance imaging : JMRI.

[27]  S. Cowper,et al.  Clinical and histological findings in nephrogenic systemic fibrosis. , 2008, European journal of radiology.

[28]  C. Robic,et al.  Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review , 2008, BioMetals.

[29]  T. Frenzel,et al.  A Preclinical Study to Investigate the Development of Nephrogenic Systemic Fibrosis: A Possible Role for Gadolinium-Based Contrast Media , 2008, Investigative radiology.

[30]  Trg Diagnostic.  Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions , 2008 .

[31]  A. Elster.  Gadolinium-enhanced MR Imaging and Nephrogenic Systemic Fibrosis: Retrospective Study of a Renal Replacement Therapy Cohort , 2008 .

[32]  M. Beck,et al.  Nonclinical Juvenile Toxicity Testing , 2008 .

[33]  L. Skov,et al.  Case-control study of gadodiamide-related nephrogenic systemic fibrosis. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[34]  W. High.  Nephrogenic systemic fibrosis and gadolinium-based contrast agents , 2007 .

[35]  D. Saunders,et al.  Magnetic resonance imaging protocols for paediatric neuroradiology , 2007, Pediatric Radiology.

[36]  S. Morcos,et al.  Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? , 2007, The British journal of radiology.

[37]  M. Port,et al.  Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review , 2006, Fundamental & clinical pharmacology.

[38]  John M Desesso,et al.  Postnatal growth and morphological development of the brain: a species comparison. , 2006, Birth defects research. Part B, Developmental and reproductive toxicology.

[39]  Lone Skov,et al.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. , 2006, Journal of the American Society of Nephrology : JASN.

[40]  T. Grobner.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[41]  W. Kaiser,et al.  Pediatric brain MRI in neurofibromatosis type I , 2005, European Radiology.

[42]  C. Chambon,et al.  Pharmacokinetics and tolerance of Gd-DOTA (DOTAREM) in healthy volunteers and in patients with chronic renal failure , 2004, European Radiology.

[43]  M. Hurtt,et al.  Species comparison of anatomical and functional renal development. , 2003, Birth defects research. Part B, Developmental and reproductive toxicology.

[44]  L. Gustafsson,et al.  Basic experimental studies and clinical aspects of gadolinium salts and chelates. , 2006, Cardiovascular drug reviews.

[45]  Michael J. Derelanko,et al.  Handbook of Toxicology , 2001 .

[46]  R. Lauffer,et al.  Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. , 1999, Chemical reviews.

[47]  C. Fleck.  Determination of the glomerular filtration rate (GFR): methodological problems, age-dependence, consequences of various surgical interventions, and the influence of different drugs and toxic substances. , 1999, Physiological research.

[48]  B. Bonnemain,et al.  Gd-DOTA. Pharmacokinetics and tolerability after intravenous injection into healthy volunteers. , 1990, Investigative radiology.

[49]  F. Gohs,et al.  Age-related changes in serum chemistry and hematology values in normal Sprague-Dawley rats. , 1987, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[50]  A. Provoost,et al.  Development of Renal Function in the Rat , 1983 .

[51]  A. Provoost,et al.  Development of renal function in the rat. The measurement of GFR and ERPF and correlation to body and kidney weight. , 1983, Renal physiology.

[52]  B. Régnier,et al.  Eye lesions in Sprague-Dawley rats: type and incidence in relation to age , 1981, Laboratory animals.

[53]  B. Friis‐Hansen.  The Extracellular Fluid Volume in Infants and Children , 1954, Acta paediatrica.